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Abstract
Background: The objective was to determine the economic burden, as well as the impact on
HRQOL for people with HIV/AIDS in Spain in 2003.
Methods: A cross-sectional study of 572 people with HIV were recruited from outpatient clinics
in the Canary Islands, Spain. Demographic, health resources utilization, indirect costs and quality of
life data were collected through medical records and questionnaires filled out by people with HIV.
HRQOL was measured with two generic questionnaires: SF-36 and EQ-5D.
Results: In 2003 annual costs of caring for patients with asymptomatic HIV, symptomatic HIV and
AIDS were €10,351, €14,489 and €15,750, respectively. The HRQOL with the EQ-5D was 0.78.
SF-36 summary results for physical and mental health were 48.30 and 38.80, respectively.
Conclusion:  HIV/AIDS represent a high economic impact from society point of view. the
structure of health care costs have changed due to these new drugs, increasing the weight of
pharmaceutical treatment over total costs and decreasing the importance of inpatient care costs.
In spite of the therapeutic improvements, labour losses/indirect costs still represent a high cost.
Costs and HRQOL were strongly associated with severity. Although the latest drug developments
have not yet been able to find the definitive cure, they have allowed an improvement in expectancy
of life and in the HRQOL of the patients.
Background
Since the discovery of human immunodeficiency virus
(HIV) at the beginning of the 1980s, HIV/AIDS has been
one of the greatest health problems in the world [1]. HIV/
AIDS places an increasing burden on the health of the
population, and causes further socio-economic problems
for individuals, families, communities and governments
in many countries [2,3].
Since the beginning of the epidemic, 67,466 cases of AIDS
have been registered in Spain, with a number of estimated
deaths ranging between 40,000 and 50,000. Spain has the
highest rate of HIV among Western European countries.
The estimated number of people infected by HIV is about
130,000 (range 110,000–150,000). However, it is
thought that only 75% of all cases have been diagnosed
and receive appropriate treatment. Epidemiological stud-
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ies in Spain show that there are approximately 97,500
people diagnosed with HIV/AIDS [4]. National informa-
tion on the HIV/AIDS disease severity distribution (39.5%
asymptomatic HIV, 19.4% symptomatic HIV and 41.1%
AIDS) enables us to distribute these people into the fol-
lowing three groups: 38,513 as asymptomatic HIV,
18,915 as symptomatic HIV and 40,073 as AIDS [5].
In high-income countries, the medical advances of recent
years have yet to produce a cure, although they have been
able to increase the life expectancy and improve the qual-
ity of life of the virus carriers, as well as delay the terminal
stage of the disease [6]. As a consequence of advances in
therapy since the mid-90s, several reports have docu-
mented a shift in HIV/AIDS health service utilization from
inpatient to outpatient care in developed countries since
the introduction of Highly Active Antiretroviral Therapy
(HAART) [7,8]. Most economic assessments carried out in
this area deal with the determination of direct costs (pre-
vention, diagnosis and treatment of HIV disease). Eco-
nomic assessments incorporating the costs associated
with productivity losses (indirect costs) are exceptions in
the health economics literature on HIV [9,10]. It is impor-
tant to stress that most of the people with HIV in Spain are
of working age (82% being between the ages of 25 and 39
years), and have been forced to leave the labour market
because of their illness [5]. However, the effects of antiret-
roviral treatments on patient survival and reduced mor-
bidity improve the chances of people to participate in the
labour market.
Assessing health-related quality of life (HRQOL) is useful
for documenting the patient's perceived burden of
chronic disease, tracking changes in health over time,
assessing the effects of treatment and quantifying the
return on health care investment [11]. The reduction in
HRQOL relative to the progression of the disease is also
relevant for the allocation of health care resources, and
should be taken into consideration by the clinicians treat-
ing people with HIV.
In spite of Spain's relatively high HIV prevalence rate
(when compared to other European countries), there have
been no recent studies on HIV-related costs in Spain. The
aim of this study was to calculate the economic costs of
people with HIV/AIDS in the Canary Islands, Spain. We
also examined the HRQOL of people with HIV/AIDS.
Methods
Research field and subjects
It was carried out a cross-sectional, retrospective study of
people diagnosed with HIV/AIDS receiving outpatient
care. Patients were recruited according to disease severity
from four hospital outpatient clinics in the Canary
Islands, Spain. The 1993 classification scheme proposed
by the Centre for Disease Control and Prevention (CDC)
in the United States to divide the disease into HIV-asymp-
tomatic, HIV-symptomatic and AIDS stages [12] was used
to establish the severity of HIV infection.
All patients were informed about the study objectives and
the confidentiality of the data and were asked to show
their agreement with, and their understanding of, the
study conditions by signing a declaration of consent form.
The study was approved by the ethics research committee
of University Hospital Nuestra Sra. de la Candelaria.
Information and variables of interest
The fieldwork was carried out between January and
December 2003. Demographic and clinical data were col-
lected for people previously diagnosed with HIV/AIDS.
The patients recruited were at least 18 years old and they
were treated in outpatient clinics.
Apart from those who did not agree to take part in the
study, incarcerated HIV people were not included in the
analysis. Also, some patients were excluded from the final
analysis when the information gathered was incomplete.
The information sources used in the study were the
patients' medical records and self-completed question-
naires. We used two different questionnaires to collect
data about the direct and indirect costs and HRQOL.
Patients were asked about their employment and wages
when HIV infection was diagnosed, as well as their current
situation, in order to collect data for the calculation of the
indirect costs.
HRQOL information was collected only once using two
generic questionnaires: EQ-5D and SF-36.
Cost Methodology
We used the prevalence approach. The prevalence of the
disease takes into account all of the existing cases during a
given year and all of the resources used for prevention,
treatment and rehabilitation, plus the productivity losses
as a result of morbidity within that year. The cost of illness
based on prevalence has the advantage of incorporating
the measurements of total annual health care expenditure,
which is particularly relevant for a chronic disease like
AIDS where long-term treatment is needed [13].
A bottom-up costing approach was used, which normally
begins from a defined subpopulation with a certain
pathology and records every cost of the disease related to
the disease pathology [14]. The point of view used here for
the analysis is from the societal perspective, and the unit
prices relate to 2003.BMC Health Services Research 2009, 9:55 http://www.biomedcentral.com/1472-6963/9/55
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Direct health-care costs
Direct costs were derived from health care utilization. The
resources used by each patient were given a value, in terms
of the relevant unit costs and the average cost per patient
in the sample, as well as in terms of the average cost per
patient at various levels of severity (asymptomatic, symp-
tomatic, AIDS and CD4 cell count). Unit prices should
reflect opportunity cost, although in practice other cost
measurements (like accounting cost) are often used.
Information about the number of hospital admissions,
medical tests and use of prescription drugs for problems
related to HIV/AIDS was taken from medical records. Unit
costs came from a number of available sources and were
based on a costing exercise. Inpatient care was based on
Diagnosis Related Group (DRG) costs. Unit costs (not
charges for reimbursement) for DRGs were valued on the
basis of the average costs per DRG from 18 hospitals in
Spain (one hospital from the Canary Islands was
included) [15].
Prescription drug costs were calculated using data from
the hospitals. The hospital drug costs were based on the
official selling price to hospitals in the Canary Islands.
We used information obtained through questionnaires
filled out by the patients with HIV/AIDS to determine the
number of emergencies, rehabilitations and medical visits
related to HIV/AIDS.
The mean costs per emergency visit, rehabilitation and
medical visit were taken from the SOIKOS health care unit
cost database [16]. SOIKOS is the most complete database
used in Spain to obtain health care unit costs. The sources
of the unit costs are published articles, reports, hospital
accounting systems, etc., and the figures are updated every
year.
Indirect costs
The survey included questions about labour participation
and individual wages, firstly, when the person received
the HIV's diagnosis and, secondly, at the time of answer-
ing the questionnaire. The theoretical basis used for the
estimation of the labour losses was the human capital
approach [17]. Based on this approach, productivity
losses can be estimated through changes in labour status
and in wages.
Patient outcomes
Two types of patient outcomes were examined in the anal-
ysis: 1) health status, as measured by the physical and
mental health summary scores from the Medical Out-
comes Study Short-Form (SF-36) [18], and 2) health util-
ities, as measured by the EQ-5D [19]. Both are well known
HRQOL generic instruments and are used to measure
HRQOL among the general population as well as in a vari-
ety of different chronic diseases.
The Short Form-36 Health Survey (SF-36) is one of the
most widely used and evaluated generic health-related
quality of life (HRQOL) questionnaires and has already
been validated and is in widespread use in Spain [20,21].
SF-36 consists of 36 questions [18], which are categorised
into 8 subscales that can be subdivided into two catego-
ries: physical and mental health measures.
EQ-5D is a simple generic instrument developed by a
multidisciplinary group of researchers [19]. EQ-5D has
been validated in Spain, and it is commonly used in the
area of economic evaluation and technology assessment.
In two regions of Spain (Catalonia and the Canary
Islands) EQ-5D is used for periodic health surveys where
the two populations are similar [22,23]. There are five
questions in EQ-5D covering the areas of mobility, self
care, everyday activities, pain/discomfort and anxiety/
depression. A total of 243 possible health states can be
defined in this way. Valuations of these health states are
given for the general population [24]. The values, or utili-
ties, are scaled such that 0 is the value of death and 1 is the
value of perfect health.
Results
Patients' characteristics
A total of 578 questionnaires were collected from people
with HIV/AIDS (72.3% of the total sent), 6 of which were
excluded because the information contained was insuffi-
cient or inadequate. The main characteristics of the sam-
ple in terms of age, gender, stages of HIV infection and
transmission categories are shown in Table 1 [see Addi-
tional file 1]. We have no information on the characteris-
tics of HIV people who did not participate in the study.
However, the proportion of patients contacted who did
not agree to participate in the study was very low.
The study randomly selected 400 patients from the 572
person who participated in the study to calculate indirect
costs. We obtained 241 patients answers (60.3% of the
total sent), 4 of which were excluded because the informa-
tion was insufficient or inadequate. This sub-sample
accounted for near of 10% of the estimated HIV cases in
the Canary Islands. No significant differences were found
between the mean age, sex and clinical variables of this
sub-sample and the sample of 572 people with HIV used
for the calculations of direct costs [see Additional file 2].
Results of the costs for people with HIV/AIDS
The mean costs were €10,531, €14,489 and €15,750 for
patients with asymptomatic HIV, symptomatic HIV and
AIDS, respectively, in 2003 [see Additional file 3]. The
health care costs increased with the severity of disease, asBMC Health Services Research 2009, 9:55 http://www.biomedcentral.com/1472-6963/9/55
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expected. Upon analysing the internal distribution of the
costs for each of these groups, the drugs were seen to be
the largest contributor to health care costs for asympto-
matic HIV, symptomatic HIV and AIDS patients. Medical
tests were the second highest in terms of importance for
asymptomatic HIV and symptomatic HIV patients,
whereas hospitalisations were the second highest for AIDS
patients. In addition, we calculated health care costs for
patients with CD4 cell count [see Additional file 4], for
comparison with other studies [25]. The CD4 cell counts
were obtained from the latest available data collected
from medical records.
Quality of life of people with HIV/AIDS
Women had lower SF-36 scores than men, with statisti-
cally significant differences in social function and emo-
tional role. Patients between 31 and 40 years of age had
higher scores in the physical component summary and in
four of the eight domains (physical function, social func-
tion, vitality and mental health). All of the SF-36 domain
scores (except bodily pain) gave different results for
asymptomatic HIV, symptomatic HIV and AIDS patients.
The mean physical component summary (PCS) scores
were 50.07, 47.44 and 46.07 for people with asympto-
matic HIV, symptomatic HIV and AIDS, respectively, in
the SF-36. The mean mental component summary (MCS)
scores were 39.52, 40.99 and 35.63 for people with
asymptomatic HIV, symptomatic HIV and AIDS, respec-
tively.
Symptomatic HIV patients had significantly lower scores
than asymptomatic HIV patients in the physical role and
general health. Patients with AIDS had lower mean scores
in all HRQOL domains than asymptomatic HIV patients
and also had lower mean scores in the social function,
mental health and mental component summaries than
symptomatic HIV patients. Univariate analyses indicated
that CD4 lymphocyte counts were significantly correlated
with physical functioning (SF-36). A weak and negative
correlation was observed between the viral load, general
health and physical functioning scores (SF-36).
QOL ratings on both the physical functioning and the
psychological well-being aspects of the SF-36 were lower
in people with AIDS, and significant differences were
obtained for patients according to the severity of HIV dis-
ease. It is possible to discriminate, using the dimensions
of the SF-36, between patients with HIV and AIDS, espe-
cially between patients with asymptomatic HIV and AIDS.
The mean social tariff scores in the EQ-5D were 0.79, 0.80
and 0.73 for patients with asymptomatic HIV, sympto-
matic HIV and AIDS, respectively. The values of HRQOL
differed significantly according to disease severity (P <
.001) and showed that the HRQOL scores, as measured by
the SF-36 and the EQ-5D, were related to disease severity
[see Additional file 5]. Direct and indirect costs, after con-
trolling for HRQOL using EQ-5D, are shown in Table 6
[see Additional file 6].
Discussion
The introduction of triple drug therapy has represented a
new era in the therapeutic management of HIV/AIDS
from an economic point of view. It seems clear that the
diffusion of new drug therapies has increased the lifetime
cost of care in comparison with the early 1990s [25-27],
primarily due to an increase in life expectancy of HIV+
people. However, it is not clear whether the HAART ther-
apy has increased the annual health care cost per patient.
In Canada Krentz [28] reported an increase of 71% for
health care costs between 1995 and 2001 (from 655 to
1119 Canadian dollars monthly), whereas Stoll [29]
described a 32% reduction in direct costs between 1997
and 2001 (from €35,865 to €24,482 per year). More
recently, Merito [8] also reported direct health care cost
reductions for HIV and AIDS management.
These discrepancies could be partially explained by inter-
national differences in the various components of the
costs. However, in some countries like France the same
discrepancy has been reported: Flori & le Vaillant [30]
found a decline of 25% in patients' health care costs
between 1995 and 2000; meanwhile, Basuyau [31]
reported a large increase in these costs when comparing
the 1992–1996 and 1996–2000 periods.
An increase in overall costs has been observed in Spain
from 1995 [32] to 1997 [33], followed by a reduction
from 1997 [33] to our data in 2003. Although costs data
for people with asymptomatic and symptomatic HIV in
Spain have been very similar in recent studies, the costs for
people with AIDS were higher in a previous study [33]
compared to our estimations. Cost differences between
1997 and 2003 are due to the reduction in the overall
costs for patients in the AIDS stage and, in particular, in
costs associated with hospital use.
We use human capital approach for estimating labour
productivity losses. Although this is the most commonly
method used for measuring and evaluating productivity
losses [13], there are alternative methods as the frictional
costs approach [34]. In the frictional costs model produc-
tivity losses due to premature death, permanent and tem-
porary sick leave are lower than in the human capital
approach. In fact, production losses would be zero, from
a long-term perspective, after an adjustment or "frictional
period".BMC Health Services Research 2009, 9:55 http://www.biomedcentral.com/1472-6963/9/55
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As a consequence of these different methodological
approaches, the empirical results obtained comparing
these two methods are very different, with lower values
using the frictional costs method [34]. So, it is not surpris-
ing that the use of different costing methods can lead to
different policy conclusions [35]. We focus on the human
capital calculation because this approach has a solid eco-
nomic tradition and takes a social perspective [36] while
frictional costs approach is not exempt from criticism. As
Liljas [37] pointed out "...rests on very strong assumptions
of the labour market which do not have a foundation in
economic theory".
Studies assessing indirect costs are fairly scarce in the
international field. Before the therapeutic advances that
involved the HAART, the impact of HIV on the labour par-
ticipation of HIV-infected people was devastating. Sci-
tovsky and Rice [38] assumed that a typical AIDS patient
is too ill to work for 60% of his or her time. Yelin [39]
reported that half of those working when they were
informed of the diagnosis left work within the following
two years. Massagli [40] stated that 76% of these people
were working at the moment of diagnosis and only 53%
at the time of the survey (with an average of 16 months
elapsing since the diagnosis). The loss of wages was calcu-
lated as being 75% for the whole sample. Leigh [41] con-
cluded that, when compared with a control group (not
HIV-infected), patients with an AIDS diagnosis experience
a substantial loss of working time, but this is also the case
with HIV-infected patients who do not develop the dis-
ease. Laursen and Larsen [42] found that 50% of the
patients were employed when they were diagnosed with
AIDS, 15% were off work and 19% were receiving sickness
benefits. The percentage of people in employment fell to
22% a month after diagnosis, and to 6% two years after-
wards, with 67% having died. Therefore, the development
of the illness reduces the life expectancy of the patients
and forces them, in many cases, to leave the job market.
However, therapeutic advances made since the mid 1990s
have substantially changed this scenario. Dray-Spira [43],
stated that between 46.8% and 58.8% of HIV+ people
(depending on the region of France considered) were
employed, and a third of those unemployed said they
were looking for work in 2001. Rabkin [44] concluded
that patients who already had work at the beginning of the
follow-up had a higher probability of keeping it. On the
other hand, people who were unemployed did not man-
age to return to their jobs or find another job. Goldman
and Bao [45] studied the effect on patients of the use of
HAARTs in terms of the probability of returning to work,
keeping the same position and number of hours worked.
Their results indicate that the probability of keeping a job
in the 6 months following the beginning of the treatment
goes up from 58% to 94% as a result of the treatment. In
addition, they clearly stated that the results are more
favourable when the treatment is started in the early
phases of the infection. A recent paper by Bernell and
Shinogle [46] came to a similar conclusion: HAARTs sub-
stantially increase the HIV-infected person's chances of
participating in the workforce. Nevertheless, this does not
mean that an HIV diagnosis does not affect the patient's
participation at work or that its impact is less. However,
Auld [47] suggested that the decrease in the percentage of
HIV-positive people in employment is a consequence of
the adaptation of expectations of the person to a health
shock that implies a lower life expectancy. Along the same
lines, Auld [47] calculated that the impact of the diagnosis
decreases the chances of finding employment by 25%.
In Spain, we are aware of only one pilot study on patients
with HIV/AIDS where Oliva et al., [10] found that the bet-
ter the HRQOL, the higher the probability of being
employed. However, in our study, productivity losses
were high among patients despite their good HRQOL.
As regards HRQOL, previous studies with comparable
data also showed equivalent values for SF-36 physical
functioning in people with asymptomatic HIV and the
general population, which then worsened with the pro-
gression of the disease [11,40]. Comparing this informa-
tion with our more recent data, we observed better
physical functioning SF-36 scores, which could be inter-
preted as the result of the impact of changes in the treat-
ments (use of new and more effective treatments, different
access to medications among countries, etc).
In line with some other studies [11], emotional well-
being, measured by SF-36, was significantly worse in peo-
ple with HIV/AIDS than in the general population in
Spain and in people with other chronic diseases (mean (±
SD) 39 (± 14) vs. 50 (± 10)). Despite improvement in
treatment outcomes, people with AIDS have worse emo-
tional well-being than patients with asymptomatic and
symptomatic HIV disease. Co-morbid psychiatric ill-
nesses, including anxiety and depression, were frequent in
HIV-positive patients [46]. Previous studies showed com-
parable levels of emotional well-being among patients in
different stages of HIV disease, although the values were
significantly worse than for the general population and
patients with other chronic diseases [11].
Furthermore, several studies showed a negative relation-
ship between symptoms and health-related quality of life
in patients with HIV disease [11,48,49]. These studies sup-
port the conceptual model that links clinical measures
with health-related quality of life, suggesting that effective
clinical management of HIV-related symptoms may
improve functioning and well-being in these patients.BMC Health Services Research 2009, 9:55 http://www.biomedcentral.com/1472-6963/9/55
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In line with our results for SF-36, EQ-5D values in people
with HIV/AIDS showed lower age-adjusted scores than for
the general population in Spain, but higher scores than for
people with certain other chronic diseases, such as neuro-
degenerative disease, cancer, stroke, heart attack, chronic
heart failure and diabetes mellitus. Although generic
measures of HRQOL such as SF-36 or EQ-5D have previ-
ously been used on people with HIV/AIDS, the interpreta-
tion of our data suggests that these generic instruments
might lack the sensitivity needed to capture potential
HRQOL differences between patients with asymptomatic
and symptomatic HIV.
Certain studies compared and commented on the use of
the SF-36 and MOS-HIV instruments in studies of persons
with HIV disease [50]. Although MOS-HIV is widely used
in monitoring HIV-infected persons, it has noteworthy
limitations that may constrain its applications to this pop-
ulation [50]. Therefore, there is insufficient evidence in
the literature to support the use of MOS-HIV, as opposed
to using SF-36, for HIV-infected persons.
Conclusion
In conclusion, HIV/AIDS represent a high economic
impact from society point of view. Our results confirm
that the main component of the health care costs in Spain
was pharmaceuticals, with a lesser emphasis on inpatient
care costs. We also show the strongly and positive associ-
ation between costs and severity of disease. Annual costs
associated with asymptomatic phase were estimated in
€10,531,  €14,489 associated with symptomatic phase
and €15,750 associated with AIDS. In spite of the thera-
peutic improvements, labour losses (indirect costs) still
represent an important economic impact range from a
32.1% (asymptomatic) to 41.3% (symptomatic) of total
costs. Although the latest drug developments have not yet
been able to find the definitive cure, they have allowed an
improvement in expectancy of life of people with HIV and
to get a better health related quality of life.
Limitations of the study
Our results were obtained from a cross-sectional study
performed in the Canary Islands (Spain), which may limit
generalisation. However, outpatient clinics at the four
teaching hospitals in the Canary Islands have been
selected to reflect potential differences in diagnostic and
therapeutic patterns. The large sample size used in our
study for the estimation of health care costs (23% of esti-
mated people HIV-infected in the Canary Islands) and
labour productivity losses (10%) ensured that all degrees
of disease severity were represented in sufficient numbers
to make it possible to obtain consistent results.
Although we have no control group for the estimation of
indirect costs, the evolution of the Spanish labour market
has been favourable to job creation since the period 1996
until the time of the survey. The effect of the business cycle
on the labour market has been clearly positive the last
years and can not be considered in general terms that a
worsening of labour participation and wages was due to
macroeconomic effects. Therefore, the effect found on
labour participation and wages can be interpreted as a
minimum threshold of labour losses associated to HIV.
The Canary Islands with a population close to 2 million
people have a very similar demographic structure, aging
rate, health expectations and infant mortality to the aver-
age values in Spain [51]. The National Health System in
any of the 17 Spanish regions guarantees free access and
universal coverage, as well as an identical health care
package for every citizen [52]. Furthermore, ratios of
health care resources (professionals, structural and tech-
nological equipment) in the Canary Islands are in line
with the average values in Spain [53]. In addition, the
organisation of health care services for HIV infected
patients is fairly homogeneous in Spain, with most of the
services provided by outpatient clinics or day care clinics
[54]. Therefore, there is no reason to assume that the cost
of the resources in our study is substantially different from
elsewhere in Spain. Further studies are needed to study
costs for longer time periods.
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